OralIdiopathic detrusor instability, Urinary incontinence, urgency and frequencyAdult: As conventional tab: 15 mg bid or tid, increase to 4 times daily if required. Max: 60 mg daily. As modified-release cap: 30 mg once daily.
|
Patients receiving potent FMO inhibitors in combination w/ potent CYP 3A4/5 inhibitors: Initially, 15 mg daily.
|
Moderate to severe: Contraindicated
|
May be taken with or without food.
|
Obstruction of bowel, significant bladder obstruction, myasthenia gravis, intestinal atony, severe ulcerative colitis, toxic megacolon, uncontrolled angle-closure glaucoma, tachyarrhythmias. Moderate to severe hepatic impairment. Pregnancy and lactation.
|
Patient w/ autonomic neuropathy and those who are susceptible to angle-closure glaucoma. May exacerbate severe CHF (NYHA IV), cardiac arrhythmia, tachycardia, hiatus hernia w/ reflux oesophagitis, prostatic hyperplasia. Patients receiving potent flavin-containing monooxygenase (FMO) inhibitors (e.g. methimazole) in combination w/ potent CYP 3A4/5 inhibitors. Hepatic and renal impairment.
|
Hypotension, drowsiness, headache, dizziness, tremor, dysgeusia, blurred vision, palpitation, dry mouth, constipation, abdominal pain, dyspepsia, nausea, vomiting, flushing, urinary retention, fatigue.
|
This drug may cause drowsiness and blurred vision, if affected, do not drive or operate machinery.
|
Monitor liver enzyme values in long-term therapy.
|
Symptoms: Restlessness, dizziness, vertigo, speech and vision disorder, muscle weakness, severe dryness of mucosa, tachycardia and urinary retention. Management: Symptomatic and supportive treatment. Perform gastric lavage using an oiled tube.
|
Reduced BP when used w/ isoniazid. Drowsiness may be enhanced by drugs w/ CNS depressant properties. May decrease the effect of prokinetics (e.g. metoclopramide). Decreased effect when used w/ cholinergic drugs. Increased effect when used w/ TCAs, tranquilisers, anticholinergics, amantadine, neuroleptics and β-adrenoceptor agonists.
|
Description: Propivexine inhibits Ca influx and modulates intracellular Ca in urinary bladder smooth cells causing musculotropic spasmolysis. It also inhibits the efferent connection of the nervus pelvicus due to anticholinergic action.
Pharmacokinetics:
Absorption: Nearly completely absorbed from the GI tract. Time to peak plasma concentration: Approx 2.3 hr. Bioavailability: Approx 41%.
Distribution: Plasma protein binding: Approx 90% (propiverine); 60% (N-oxide metabolite).
Metabolism: Undergoes extensive first-pass metabolism. Metabolised by intestinal and hepatic enzymes.
Excretion: Via urine, bile and faeces. Elimination half-life: Approx 20 hr.
|
|
|
|
|
G04BD06 - propiverine ; Belongs to the class of urinary antispasmodics.
|
Anon. Propiverine. Lexicomp Online. Hudson, Ohio. Wolters Kluwer Clinical Drug Information, Inc. https://online.lexi.com. Accessed 21/07/2016. Buckingham R (ed). Propiverine Hydrochloride. Martindale: The Complete Drug Reference [online]. London. Pharmaceutical Press. https://www.medicinescomplete.com. Accessed 21/07/2016. Joint Formulary Committee. Propiverine Hydrochloride. British National Formulary [online]. London. BMJ Group and Pharmaceutical Press. https://www.medicinescomplete.com. Accessed 21/07/2016.
|
Sign Out
